The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Emanuele ZuccaDuring the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub spoke with Emanuele Zucca, Institute of Oncology Research, Bellinzona, CH. We asked, can radiotherapy be avoided in patients with primary mediastinal large B cell lymphoma (PMBCL).
IELSG37 trial: Can radiotherapy be avoided in patients with PMBCL?
Patients with PMBCL usually have good survival outcomes after initial treatment but can relapse following first-line immunochemotherapy and develop a poor prognosis. Here, Zucca discusses the current use of radiotherapy for the treatment of patients with PMBCL after first-line treatment, explaining that the efficacy of this treatment has yet to be fully elucidated. He goes on to explore the IELSG37 trial (NCT01599559), which compared radiotherapy to observational treatment to reveal if it significantly consolidates patient response to prevent remission and whether it should still be considered for treatment.